A Phase II Study of Durvalumab (MEDI 4736) with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma

Grant

Date/time Interval

  • August 14, 2020 - August 13, 2023
  • Total Award Amount

  • 130247.00
  • Direct Costs

  • 95770.00
  • Sponsor Award Id

  • Contributor

  • Andrew McDonald   Investigator  
  • Christopher Willey M.D., Ph.D.   Investigator  
  • Drexell Boggs   Investigator  
  • James Bonner M.D.   Principal Investigator  
  • Kimberly Keene M.D.   Investigator  
  • Michael Dobelbower M.D.   Investigator  
  • Sharon Spencer M.D.   Investigator